At the “Molecular Diagnostics Innovation Technology and Application Forum” held today, Dr. Tammy Tan, Chairman of HymonBio Co., Ltd., served as a guest speaker. She shared the latest advances in AI-enabled tumor screening technology and introduced the world’s leading pan-cancer early screening product on the PCR. This innovative technology has revolutionized the field of early cancer screening and has attracted significant attention in the industry.
In her report, Dr. Tan emphasized the necessity of cancer screening and pointed out the difference between early cancer screening and early cancer diagnosis, stating that early cancer screening can benefit a wider population. She then reviewed the shortcomings of traditional screening methods, including their difficulty meeting the requirements for pan-cancer screening. She also provided a detailed introduction to the development of emerging screening technologies, including Cologuard, a benchmark product for early colorectal cancer screening, and Galleri, the world’s first pan-cancer early screening product on the NGS. Finally, given the limitations of current multi-cancer screening programs, Dr. Tan highlighted HymonBio’s new Pan-Cancer Screening Test Kit.
This product uses a single 5mL tube of peripheral blood to screen for 28 common cancers. The cost of this test is only 4% of similar products in the United States, achieving a historic breakthrough in pan-cancer early screening both domestically and internationally. The company’s core technologies include ESC Magnetic Bead Extraction Technology, Molecular Lock Amplification Technology, efficient methylation amplification technology, and a multi-target detection system for over 400 tumor-specific methylation markers. These technologies, deeply integrated with the latest artificial intelligence technology, enable precise and automated interpretation. The product is currently applying for US FDA Breakthrough certification.
During clinical validation, Dr. Tan demonstrated the exceptional reliability of the Pan-Cancer Screening Test Kit through multiple real-world case studies. From the highly consistent strong positive test results in patients with recurrent oral cancer, to the successful early intervention of patients with gastric precancerous lesions using weak positive results, to the complete agreement between benign thyroid nodules and the diagnosis of a leading Japanese specialist hospital, these robust clinical data fully validate the accuracy and significant clinical value of the kit’s test results.
In the future, as the Pan-Cancer Screening Test Kit progresses in certification, it will be introduced to even more health checkup scenarios. With technological advancements, its accuracy is expected to further improve, and its cost-effectiveness will make it more affordable for a wider audience, transforming it from a niche product to a widely accessible option, truly fulfilling Dr. Tan’s vision of “more early cancer screening for more people.”
Post time: Aug-21-2025